Table 3.

Multivariate Analysis: 6/8 and 7/8 HLA-matched transplants

Variables	Events/Evaluable	Hazard Ratio (95% confidence interval)	p-value
Overall Mortality*
KIR ligand matched	66/114	1.00
KIR ligand mismatched	51/85	0.95 (0.66 – 1.37)	0.79
Treatment failure**
KIR ligand matched	71/113	1.00
KIR ligand mismatched	52/85	0.87 (0.61 – 1.25)	0.45
Relapse***
KIR ligand matched	45/113	1.00
KIR ligand mismatched	37/85	0.96 (0.61 – 1.51)	0.87
NRM
KIR ligand matched	26/113	1.00
KIR ligand mismatched	15/85	0.69 (0.36 – 1.30)	0.25
Grade 2–4 acute GVHD#
KIR ligand matched	40/114	1.00
KIR ligand mismatched	30/85	0.99 (0.61 – 1.60)	0.97
Chronic GVHD##
KIR ligand matched	15/114	1.00
KIR ligand mismatched	21/85	1.66 (0.85 – 3.24)	0.14

^*Model adjusted for disease status (CR2 vs. CR1 HR 1.91, 95% CI 1.15 – 3.19, p=0.01; relapse vs. CR1 HR 4.82, 95% CI 3.01 – 7.71, p<0.0001)

^**Model adjusted for disease status (CR2 vs. CR1 HR 1.91, 95% CI 1.15 – 3.19, p=0.01; relapse vs. CR1 HR 4.82, 95% CI 3.01 – 7.71, p<0.0001)

^***Model adjusted for disease status (CR2 vs. CR1 HR 2.80, 95% CI 1.40 – 5.58, p=0.004; relapse vs. CR1 HR 10.04, 95% CI 5.31 – 19.00, p<0.0001); sex (male vs. female HR 1.68, 95% CI 1.08 – 2.63, p=0.02)

^#Model adjusted for in vivo T-cell depletion vs. none (HR 1.79, 95% CI 1.07 – 3.01, p=0.03); patient age (>16 vs. ≤16 years HR 0.50, 95% CI 0.27 – 0.91, p=0.02)

^##Model adjusted for in vivo T-cell depletion vs. none (HR 2.35, 95% CI 1.20 – 4.58, p=0.01)